Phase 4 Crohn's Disease and Colitis Trial, By Invitation
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are 21 years of age or older at the time of joining the trial
- People who have been diagnosed with ulcerative colitis (UC) or Crohn's disease (CD)
- People for whom a treating doctor determines that a biologic therapy is appropriate, because earlier standard treatments and/or other biologic treatments have not worked well enough (not counting a specific group of medicines called IL-23p19 antagonists)
- People who have never taken mirikizumab and have no medical reasons preventing them from taking it
- People who are able to give their informed consent to participate
- People who are willing to follow the study procedures and attend required follow-up appointments
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have previously taken medicines belonging to the IL-23p19 antagonist group, such as mirikizumab, risankizumab, or guselkumab
- People who have previously taken certain newer oral medicines for IBD, such as JAK inhibitors or S1P receptor modulators
- People who have taken part in another interventional clinical trial within the 90 days before joining this trial
- People who have had extensive bowel surgery, including full removal of the colon and rectum (for UC), or surgical removal of two or more sections of the intestine (for Crohn's disease)
- People who have any other condition that, in the treating doctor's judgement, could affect their safety, the reliability of the study data, or their ability to take part in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Casey Chapman, MD, GIA
Phone: 914-388-4907
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Proportion of Patients Requiring an Increase in IBD Disease Management
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.